Omnicell (OMCL) closed the last trading session at $31.01, gaining 3.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $44.8 indicates a 44.5% upside potential.The mean estimate comprises five short-term price targets with a standard deviation of $9.73. While the lowest estimate of $34.00 indicates a 9.6% increase from the current price level, the most optimistic analyst expects t ...

Shares of Beyond (BYON) have gained 18.9% over the past four weeks to close the last trading session at $8.95, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $14.08 indicates a potential upside of 57.3%.The average comprises six short-term price targets ranging from a low of $5.00 to a high of $36.00, with a standard deviation of $11.06. While the lowest estimate indicates a de ...

Dyne Therapeutics, Inc. (DYN) closed the last trading session at $9.91, gaining 10.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $38.21 indicates a 285.6% upside potential.The mean estimate comprises 17 short-term price targets with a standard deviation of $14.79. While the lowest estimate of $9.00 indicates a 9.2% decline from the current price level, the most optimistic anal ...

股价表现与分析师目标价 - Genius Sports Limited (GENI) 过去四周股价上涨0.7%至10.17美元 但华尔街分析师平均目标价12.82美元显示潜在上涨空间达26.1% [1] - 17份目标价预测区间为11美元至15美元 标准差1.13美元 最低预测涨幅8.2% 最高预测涨幅47.5% [2] - 分析师对GENI的盈利预期修正呈现一致上调趋势 当前年度Zacks共识盈利预期过去一个月上调6.2% [11][12] 分析师目标价的可信度分析 - 实证研究表明分析师目标价常误导投资者 且与实际股价走势相关性较低 [7] - 华尔街分析师可能因商业利益关系设定过于乐观的目标价 特别是与覆盖公司存在业务往来的机构 [8] - 低标准差(1.13美元)显示分析师对GENI价格变动方向和幅度的共识度较高 可作为基本面研究的起点 [9] 盈利预期与评级支撑 - GENI当前Zacks评级为2级(买入) 位列覆盖的4000多只股票前20% 该评级基于盈利预期相关四项因素 [13] - 盈利预期修正趋势与短期股价走势存在强相关性 近期无负面修正且一致上调强化看涨逻辑 [11][12] - 尽管目标价本身可靠性存疑 但其指示的价格变动方向仍具参考价值 [14]

Nomad Foods (NOMD) closed the last trading session at $17.49, gaining 0.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $24 indicates a 37.2% upside potential.The mean estimate comprises six short-term price targets with a standard deviation of $2.37. While the lowest estimate of $20.00 indicates a 14.4% increase from the current price level, the most optimistic analyst expects ...

HNI (HNI) closed the last trading session at $51.83, gaining 1.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $68.75 indicates a 32.7% upside potential.The average comprises four short-term price targets ranging from a low of $60.00 to a high of $80.00, with a standard deviation of $8.54. While the lowest estimate indicates an increase of 15.8% from the current price level, the ...

Geo Group (GEO) closed the last trading session at $26.1, gaining 9.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $41.8 indicates a 60.2% upside potential.The mean estimate comprises five short-term price targets with a standard deviation of $6.42. While the lowest estimate of $35.00 indicates a 34.1% increase from the current price level, the most optimistic analyst expects t ...

公司股价表现与目标价分析 - Mineralys Therapeutics Inc (MLYS) 最新收盘价为14 26美元 过去四周累计上涨1 9% [1] - 华尔街分析师给出的平均目标价为36 25美元 隐含154 2%上行空间 最低目标价15美元(5 2%涨幅) 最高目标价48美元(236 6%涨幅) [1][2] - 8个目标价的标准差为11 25美元 标准差越小表明分析师共识度越高 [2][9] 分析师目标价的可信度 - 实证研究表明 分析师目标价对股价预测的准确性长期存疑 常误导投资者 [7] - 华尔街分析师可能因商业利益(如维护客户关系)设定过度乐观的目标价 [8] - 投资者不应仅依赖目标价决策 但低标准差的目标价集群可作为研究起点 [9][10] 盈利预测修正与评级 - 当前财年Zacks共识盈利预测30天内上调1 6% 无负面修正 [11][12] - MLYS获Zacks2(买入)评级 位列4000多只股票前20% 短期上行潜力获量化模型支持 [13] - 盈利预测修正趋势与股价走势存在强相关性 形成基本面支撑 [11][14] 投资价值判断依据 - 尽管目标价可靠性存疑 但其指示的价格方向仍具参考价值 [14] - 盈利预测上修共识强化了股价上行逻辑 但需结合其他基本面因素综合判断 [4][11]

Shares of Alvotech (ALVO) have gained 0.3% over the past four weeks to close the last trading session at $9.16, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $17.5 indicates a potential upside of 91.1%.The mean estimate comprises four short-term price targets with a standard deviation of $7. While the lowest estimate of $14.00 indicates a 52.8% increase from the current price ...

Shares of On Holding (ONON) have gained 0.3% over the past four weeks to close the last trading session at $51.64, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $64.64 indicates a potential upside of 25.2%.The mean estimate comprises 22 short-term price targets with a standard deviation of $6.45. While the lowest estimate of $50.00 indicates a 3.2% decline from the current pri ...